Versant Venture Capital VI, L.P. sold $7.4M of LENZ
owner at LENZ Therapeutics, Inc.. 188,094 shares at an average of $39.47, traded Aug 22, 2025, filed Aug 26, 2025.
Score components
- +12Role10% owner
- +25Trade size$7.4M at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-111529, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | SOpen-market sale Common Stock | -20,493 | $40.03 | $820k | 1,379,727 | Aug 26, 2025 |
| Aug 22, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -10,076 | $40.03 | $403k | 952,802 | Aug 26, 2025 |
| Aug 22, 2025 | SOpen-market sale Common Stock | -5,668 | $40.59 | $230k | 1,374,059 | Aug 26, 2025 |
| Aug 22, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -2,809 | $40.59 | $114k | 949,993 | Aug 26, 2025 |
| Aug 25, 2025 | SOpen-market sale Common Stock | -50,270 | $39.53 | $2.0M | 1,323,789 | Aug 26, 2025 |
| Aug 25, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -24,760 | $39.53 | $979k | 925,233 | Aug 26, 2025 |
| Aug 25, 2025 | SOpen-market sale Common Stock | -2,149 | $39.92 | $86k | 1,321,640 | Aug 26, 2025 |
| Aug 25, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -1,058 | $39.92 | $42k | 924,175 | Aug 26, 2025 |
| Aug 26, 2025 | SOpen-market sale Common Stock | -43,978 | $38.97 | $1.7M | 1,277,662 | Aug 26, 2025 |
| Aug 26, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -21,661 | $38.97 | $844k | 902,514 | Aug 26, 2025 |
| Aug 26, 2025 | SOpen-market sale Common Stock | -3,465 | $39.50 | $137k | 1,274,197 | Aug 26, 2025 |
| Aug 26, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -1,707 | $39.50 | $67k | 900,807 | Aug 26, 2025 |
Related signals
Other insiders at LENZ Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | LENZ Therapeutics, Inc. | Shawn Olsson Chief Commercial Officer | $261k 10,000 shares | -68% | |
| 44Moderate | LENZ Therapeutics, Inc. | James W McCollum director | $239k 10,500 shares | - | |
| 47Moderate | LENZ Therapeutics, Inc. | Daniel R. Chevallard Chief Financial Officer | $50k 2,198 shares | +69% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 224,974 shares | -19% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $5.7M 135,304 shares | -11% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 260,713 shares | -17% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $6.5M 191,376 shares | -11% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $6.1M 200,000 shares | -10% | |
| 47Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 334,801 shares | -27% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 350,000 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.